AlzeCure Pharma
4.11.2021 10:21:53 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 04, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company's latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021 . The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day 2021 on November 11
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/671149/AlzeCure-Presents-at-Redeye-Life-Science-Day-2021-on-November-11
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ComplianceQuest and Zolon PCS Selected to Modernize U.S. Food and Drug Administration (FDA) Enterprise Quality Management System6.10.2026 18:00:00 CEST | Press release
TAMPA, FL / ACCESS Newswire / October 6, 2026 / ComplianceQuest, a leading provider of AI-powered connected Quality, Risk and Compliance (QRC) systems, and Zolon PCS, a provider of secure, mission-focused IT services to federal agencies, today announced that the U.S. Food and Drug Administration (FDA) will modernize its enterprise quality management operations on the ComplianceQuest platform. The initiative will be delivered under the FDA Cloud Quality Management System Blanket Purchase Agreement (BPA), a five-year agreement awarded to Zolon PCS as prime contractor, with ComplianceQuest as its platform partner. Together, ComplianceQuest and Zolon PCS will help FDA implement a modern, secure, AI-enabled quality management solution built on the Salesforce FedRAMP Government Cloud platform. The solution is designed to strengthen compliance, improve consistency, streamline quality processes, and deliver greater insight across FDA's centers and offices. The initiative will focus on four pri
Stagwell Launches New Global Media Agency, Stagwell Media6.10.2026 15:45:00 CEST | Press release
NEW YORK CITY, NY / ACCESS Newswire / October 6, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the launch of Stagwell Media, its global media agency that delivers performance built to unlock ambition. The name Stagwell Media marks a new approach to media building on the Assembly agency, bringing together its performance heritage and ecosystem expertise while debuting a new agile, integrated model powered by next generation agentic technology, Stagwell's Machine OS. Designed for the rapidly changing media landscape, Stagwell Media delivers performance with the speed, flexibility and intelligence required to succeed in a world where brands must engage priority audiences while influencing the agentic systems that shape discovery, recommendation and activation.By transforming media into a more connected and adaptive growth engine, the agency empowers brands to unlock greater ambition and drive stronger business results. "The
Valsoft Corporation Announces Acquisition of the Firebrand Group Collection of Companies6.10.2026 14:50:00 CEST | Press release
MONTRÉAL, QC / ACCESS Newswire / October 6, 2026 / Valsoft Corporation Inc. ("Valsoft"), a Montreal-based company specializing in the acquisition and development of vertical market software businesses, today announced the acquisition of Firebrand Technologies ("Firebrand"), NetGalley LLC ("NetGalley"), and Supadu Ltd ("Supadu"), together known as the Firebrand Group, a global collection of companies providing leading software and services that help publishers succeed. Valsoft acquired the Firebrand Group from Media Do International, the US-based subsidiary of MEDIA DO Ltd., in Japan. Founded in 1987 and headquartered in Newburyport, Massachusetts, Firebrand Technologies provides title management and metadata software publishers use to plan, manage, and distribute book data to retailers and trading partners around the world. Its flagship platform, Title Management Enterprise, runs the publishing workflow from acquisition through publication, keeping schedules, rights, costs,
U.S. Polo Assn. Celebrates an Outstanding 2026 European Polo Season6.10.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / October 6, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), supported several major sports events across Europe during the 2026 summer season, reinforcing the brand's authentic connection to the sport across the continent. U.S. Polo Assn. served as the Official Apparel and Jersey Sponsor for multiple events, including:55th Sotogrande International Polo Tournament at Ayala Polo Club in Sotogrande, Spain;Barnes French Open at Polo Club de Chantilly in France;Engel & Völkers Berlin Maifeld Polo Cup in Germany;Museumplein Polo Amsterdam in the Netherlands; Barnes French Open Winners, Kazak, on stage with trophy at Polo Club de Chantilly in France Across these partnerships, U.S. Polo Assn. outfitted players, umpires, and event staff while supporting competition ranging from historic high-goal championships in iconic venues throughout the region. "U.S. Polo Assn.'s presence across Europe reflects both the
Synexis and Customate Collaborate to Advance Continuous Indoor Pathogen Control for the U.K. Poultry Industry5.10.2026 22:10:00 CEST | Press release
OVERLAND PARK, KS AND YORKSHIRE, ENGLAND / ACCESS Newswire / October 5, 2026 / Synexis®, LLC, the leader in touchless, continuous pathogen control technology, has announced a strategic collaboration with Customate Solutions, a family-owned engineering company and trusted provider of innovative manufacturing solutions with deep expertise across the poultry industry. The collaboration will bring Synexis patented DHP® technology to poultry producers throughout the United Kingdom and Ireland, helping hatcheries, poultry farms, processing facilities, and related operations strengthen indoor pathogen control while supporting modern biosecurity strategies. Poultry producers today face increasing pressure to maximize healthy hatch rates, improve chick quality, and strengthen biosecurity while reducing operational risk. Bacterial contamination on hatching eggs and throughout hatchery environments can directly impact hatchability, flock health, and production performance, making effective pathog
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom